Drug intelligence / Profile preview

177Lu-FAP-VG-02

Development stage: Preclinical
Lead developer: VitsGen Therapeutics
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

177Lu-FAP-VG-02 is a preclinical-stage radionuclide drug conjugate (RDC) developed by VitsGen Therapeutics for the treatment of tumors expressing fibroblast activation protein (FAP). The therapeutic consists of a targeting moiety specific to FAP conjugated to the beta-emitting radioisotope Lutetium-177 (177Lu). By binding to FAP, which is highly expressed in the tumor stroma and various cancer cells, the drug delivers localized ionizing radiation to induce DNA damage and cell death in FAP-positive tumors while minimizing off-target effects. VitsGen Therapeutics aims for an IND filing in late 2024, with clinical trials projected to begin in late 2025.

Other names: 177Lu-FAP-VG-02

Targets

FAP (Fibroblast activation protein alpha)

Beyond the preview

Go deeper on 177Lu-FAP-VG-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 177Lu-FAP-VG-02.

Explore the full profile